ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Tislelizumab reduces risk of death by 30 percent in oesophageal cancer trial
June 08, 2021In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma. -
Novartis Tislelizumab Meets Primary Endpoint of Overall Survival in Esophageal Cancer
June 08, 2021Novartis announced results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001).
Pharma Sources Insight January 2025
